Showing results (1161-1170 of 1,274) with videos related to

Sort By:
Pageof 128
Blood|September 1, 2005
Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemiaJohn G Gribben, David Zahrieh, Katherine Stephans, et al.
The Journal of Clinical Endocrinology and Metabolism|March 25, 2025
Race-Neutral Pediatric Reference Ranges for Bone Mineral Density Predict Prospective Fractures in ChildhoodBabette S Zemel, Karen K Winer, Andrea Kelly, et al.
British Journal of Haematology|January 6, 2016
A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphomaPhilippe Armand, Robert Redd, Jad Bsat, et al.
Bone Marrow Transplantation|July 23, 1998
CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphomaR J Soiffer, A S Freedman, D Neuberg, et al.
American Journal of Respiratory and Critical Care Medicine|March 2, 2018
Disease Management plus Recommended Care versus Recommended Care Alone for Ambulatory Patients with Chronic Obstructive Pulmonary DiseaseOfra Kalter-Leibovici, Michal Benderly, Laurence S Freedman, et al.
International Journal of Oral Science|March 1, 2026
Soluble Notch agonist enables human ameloblast maturation and enamel-like tissue formation for tooth regenerationAnjali P Patni, Rubul Mout, Ammar Alghadeer, et al.
American Journal of Epidemiology|June 12, 2014
Pooled results from 5 validation studies of dietary self-report instruments using recovery biomarkers for energy and protein intakeLaurence S Freedman, John M Commins, James E Moler, et al.
Multiple Sclerosis and Related Disorders|July 23, 2025
Ponesimod as add-on treatment in patients with active relapsing multiple sclerosis under dimethyl fumarate (POINT): A phase 3, randomized, placebo-controlled clinical trialLudwig Kappos, Michel Burcklen, Daniele D'Ambrosio, et al.
Journal of Neurology|June 5, 2020
COVID-19 in teriflunomide-treated patients with multiple sclerosisAmir Hadi Maghzi, Maria K Houtchens, Paolo Preziosa, et al.
Trials|May 11, 2019
MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosisAntonio Uccelli, Alice Laroni, Lou Brundin, et al.
Pageof 128